Cargando…

Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists

Therapeutic agents for refractory prolactinomas that are resistant to dopamine agonists (DAs) are troublesome, and surgery often only removes a large part of the tumor without complete remission. Among the various second-line treatment regimens, the treatment effect of the alkylating agent temozolom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Hao, Cheng, Yijun, Huang, Jinyan, Li, Jianfeng, Zhang, Benyan, Wu, Zhe Bao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996095/ https://www.ncbi.nlm.nih.gov/pubmed/33776913 http://dx.doi.org/10.3389/fendo.2021.616339

Ejemplares similares

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Prolactinomas Resistant to Treatment With Dopamine Agonists: Long-Term Follow-Up of Six Cases
por: Gonzaga, Maria de Fátima de Magalhães, et al.
Publicado: (2018)

Effect of Tamoxifen on the Management of Dopamine Agonist-Resistant Prolactinomas: A Systematic Review
por: Bazuhair, Tuqa, et al.
Publicado: (2023)

Is prolactin receptor signaling a target in dopamine-resistant prolactinomas?
por: Ferraris, Jimena
Publicado: (2023)

Predictors of dopamine agonist resistance in prolactinoma patients
por: Vermeulen, Elle, et al.
Publicado: (2020)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
por: Barabash, Nadiya Ye., et al.
Publicado: (2022)

Dopamine agonist resistant prolactinomas: any alternative medical treatment?
por: Souteiro, P., et al.
Publicado: (2019)

Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?
por: De Sousa, Sunita M C
Publicado: (2022)

PMON169 D2R Expression in Dopamine-Agonist Resistant Prolactinomas
por: Levine, Alice, et al.
Publicado: (2022)

Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists
por: Babey, Muriel, et al.
Publicado: (2010)

Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas
por: Gao, Hua, et al.
Publicado: (2015)

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
por: Pivonello, Claudia, et al.
Publicado: (2022)

FRI303 PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance
por: de Castro Moreira, Andrea Ramos, et al.
Publicado: (2023)

Dopamine Agonists for Pituitary Adenomas
por: Cooper, Odelia, et al.
Publicado: (2018)

Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases
por: Davoudi, Zahra, et al.
Publicado: (2022)

Managing Prolactinomas during Pregnancy
por: Almalki, Mussa Hussain, et al.
Publicado: (2015)

Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists
por: Park, Kawngwoo, et al.
Publicado: (2021)

Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report
por: Koguchi, Motofumi, et al.
Publicado: (2019)

Temozolomide: Anti-tumor effect on giant, invasive and resistant pediatric prolactinoma
por: Chentli, Farida, et al.
Publicado: (2013)

Sellar Glomus Tumor Misdiagnosed as Pituitary Adenoma: A Case Report and Review of the Literature
por: Cheng, Yijun, et al.
Publicado: (2022)

PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas
por: Zhu, Kejing, et al.
Publicado: (2022)

Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes
por: Das, Liza, et al.
Publicado: (2021)

Pituitary Prolactinoma with Amyloid Deposits: Surgery or Dopamine Agonists? Review of Previous Reports and New Recommendations for Management
por: Prabhu, Santosh, et al.
Publicado: (2019)

SUN-448 Giant Prolactinomas: A Follow-Up of 25 Years with Dopamine Agonists
por: Mallea Gil, Susana, et al.
Publicado: (2019)

Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis
por: Byberg, Sarah, et al.
Publicado: (2019)

The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
por: Zou, Yunzhi, et al.
Publicado: (2021)

Change in Insulin Sensitivity and Lipid Profile After Dopamine Agonist Therapy in Patients With Prolactinoma
por: Khalil, Ghayyur, et al.
Publicado: (2021)

Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment
por: Ali, Muzaffar, et al.
Publicado: (2021)

The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
por: Wang, Shuman, et al.
Publicado: (2021)

Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date
por: Chen, Cheng, et al.
Publicado: (2017)

SAT-247 Use of Double Dopamine Agonists in Giant Prolactinomas: A Series of 6 Cases
por: Kuan, Yueh Chien
Publicado: (2020)

MON-293 The Prevalence of Impulse Control Disorders in Patients with Acromegaly and Prolactinomas Treated with Dopamine Agonists
por: Ozkaya, Hande Mefkure, et al.
Publicado: (2020)

Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis
por: Cai, Xiangming, et al.
Publicado: (2022)

Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas
por: Medina, Eduardo J., et al.
Publicado: (2023)

Metabolic effects of prolactin and the role of dopamine agonists: A review
por: Kirsch, Polly, et al.
Publicado: (2022)

Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery
por: Zielinski, Grzegorz, et al.
Publicado: (2020)

Machine Learning for Outcome Prediction in First-Line Surgery of Prolactinomas
por: Huber, Markus, et al.
Publicado: (2022)

Diagnostic criteria of small sellar lesions with hyperprolactinemia: Prolactinoma or else
por: Cho, Anna, et al.
Publicado: (2022)

Delayed presentation of late-onset cerebrospinal fluid rhinorrhoea following dopamine agonist therapy for giant prolactinoma
por: Prague, J K, et al.
Publicado: (2014)

The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study
por: Ke, Xiaoan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1lvng2uvbpmksbs9l6k63ti1l9